AdJane's Innovative Mucosal Vaccination Strategy for Next-Gen Respiratory Immunization

AdJane Biosciences, a leader in next-generation vaccine platforms, has unveiled a groundbreaking strategy to improve respiratory vaccination. With a focus on multi-valent vaccines that stimulate both systemic and mucosal immunity, AdJane's approach could significantly enhance public health efforts to combat respiratory infections.

Introduction to AdJane's Technology

On September 10, 2026, AdJane released a comprehensive white paper titled Boosting mRNA Mucosal Immunity and a Platform Beyond It, outlining the potential of its clinically validated Nm-nOMV platform derived from Neisseria meningitidis. This innovative strategy aims to supplement existing intramuscular respiratory vaccines with a mucosal booster, thereby enhancing the immune response at the mucosal level where respiratory pathogens first enter the body.

Current intramuscular vaccines are known for their ability to generate strong systemic immunity, effectively protecting individuals from severe disease. However, they often provide limited mucosal immunity, a crucial factor in reducing transmission at the site of entry. AdJane posits that by integrating mucosal components into existing vaccination regimens, the ability to mitigate both disease severity and transmission can be improved significantly.

The Prime-Boost Approach

AdJane's strategy revolves around a prime-boost method, which employs an initial intramuscular vaccination followed by a mucosal boost via a nasal spray using Nm-nOMV technology. This not only aims to induce a robust immune response in the respiratory mucosa but also capitalizes on the extensive infrastructure and reach of existing intramuscular vaccines.

Anita Gashi, CEO of AdJane, stated, “We believe that enhancing respiratory vaccines by adding a nasal booster could create a next-generation vaccination regimen that complements the current immunization strategies.”

Clinical Support and Initial Findings

The recently conducted Phase I clinical study provides initial clinical support for this mucosal booster concept. It highlighted that participants who had previously received mRNA vaccines (like those from Pfizer or Moderna) responded well to subsequent intranasal vaccinations with Nm-nOMV expressing the SARS-CoV-2 spike protein. This response was characterized by significant levels of IgA antibodies in the nasal mucosa, which are crucial for mucosal immunity.

These findings are indicative of a promising path for complementing existing vaccination frameworks. If validated further, AdJane's strategy could potentially apply to various respiratory diseases, not limited to COVID-19, but extending to flu, RSV, and other viral respiratory pathogens.

Broader Applications of the Nm-nOMV Platform

The potential applications of AdJane's Nm-nOMV technology extend well beyond mucosal vaccination. The company is actively exploring various modalities and applications targeting infectious diseases, underpinned by a proprietary manufacturing technology and a growing intellectual property portfolio. This positions AdJane at the forefront of vaccine innovation, allowing the possibility of developing enhanced vaccine formulations that incorporate both systemic and mucosal components.

As Gashi emphasized,